The company “Pharmapark” plans to steadily increase its production volumes. Specifically, over 30,000 packages of infliximab-based medicines are expected to be introduced into civilian circulation in Russia by the end of 2025, according to TASS, citing the press service of the Ministry of Industry and Trade of Russia. Earlier, media reports highlighted a shortage of medications containing this active substance.
“Pharmapark” intends to start increasing the production volumes of this medicine as early as the second quarter of 2025. The manufacturer is currently working on this possibility. The company is preparing to submit an application to the Ministry of Health of Russia to amend the drug’s registration certificate. It is expected that the monthly production capacity could potentially be doubled as a result.
Last week, the newspaper “Izvestia” reported that there was a shortage of infliximab-based drugs in Russian medical institutions. These medications are prescribed for the treatment of Bechterew’s disease, rheumatoid arthritis, and other autoimmune diseases. The manufacturer – the Russian company Biocad – stated that the shortage was caused by issues with raw material delivery. Experts interviewed by the publication noted that while there is a wide range of alternative medications available in the country, changing therapies could lead to disease exacerbation and the occurrence of side effects.
Source: GxP news, March 24, 2025.
